Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012)
Bristol Myers Squibb (CELG-RI) posted quarterly Curent Deferred Tax Liability of -$10.0 million for Q4 2012, down 66.67% YoY from -$30.0 million in Q1 2012, and down 66.67% sequentially from -$6.0 million in Q4 2011.
Bristol Myers Squibb (CELG-RI) Curent Deferred Tax Liability (2009 - 2012) Analysis & Trends
Bristol Myers Squibb has disclosed Curent Deferred Tax Liability across 4 years of filings, most recently posting -$10.0 million for Q4 2012.
- In Q4 2012, Curent Deferred Tax Liability fell 66.67% year-over-year to -$10.0 million; the TTM figure through Dec 2012 stood at -$10.0 million (down 66.67% YoY), while the FY2012 annual figure was -$10.0 million, down 66.67% from the prior year.
- Curent Deferred Tax Liability declined to -$10.0 million in Q4 2012, from -$6.0 million in the prior quarter.
- Over the last five years, Curent Deferred Tax Liability for CELG-RI reached as high as $8.0 million in Q4 2009 and fell as low as -$10.0 million in Q4 2012.
- The 4-year median for Curent Deferred Tax Liability is -$5.5 million (2010), against an average of -$3.2 million.
- Annual changes were most pronounced in 2010 — Curent Deferred Tax Liability slumped 162.5% — and 2011, when it dropped 20.0%.
- A 4-year view of Curent Deferred Tax Liability shows it stood at $8.0 million in 2009, then tumbled by 162.5% to -$5.0 million in 2010, then decreased by 20.0% to -$6.0 million in 2011, then tumbled by 66.67% to -$10.0 million in 2012.
- According to Business Quant data, Curent Deferred Tax Liability over the past three periods registered -$10.0 million, -$6.0 million, and -$5.0 million for Q4 2012, Q4 2011, and Q4 2010 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Curent Deferred Tax Liability (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Bristol Myers Squibb | 244.56 Mn | -10.21 Bn | 8.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2012 | -10.00 Mn |
| Dec 31, 2012 | -10.00 Mn |
| Dec 31, 2011 | -6.00 Mn |
| Dec 31, 2011 | -6.00 Mn |
| Dec 31, 2010 | -5.00 Mn |
| Dec 31, 2010 | -5.00 Mn |
| Dec 31, 2009 | 8.00 Mn |
| Dec 31, 2009 | 8.00 Mn |